Brief: Arch Biopartners Submits IND Application For Metablok
08/06/2020 12:21
June 8 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS SUBMITS INVESTIGATIONAL NEW DRUG
APPLICATION TO
THE FDA FOR METABLOK (LSALT PEPTIDE)
* ARCH BIOPARTNERS -SUBMITTED IND APPLICATION FOR METABLOK
TO
CONDUCT PHASE II TRIAL TO PREVENT ACUTE ORGAN INFLAMMATION,
INJURY EXPERIENCED BY PATIENTS WITH COVID-19
Source text for Eikon: ID:nGNX4H6CDS
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide